Chemoenzymatic synthesis of chiral 2,2'-bipyridine ligands and their *N*-oxide derivatives: applications in the asymmetric aminolysis of epoxides and asymmetric allylation of aldehydes[†]‡

D. R. Boyd,*^{*a*} N. D. Sharma,^{*a*} L. Sbircea,^{*a*} D. Murphy,^{*a*} J. F. Malone,^{*a*} S. L. James,^{*a*} C. C. R. Allen^{*b*} and J. T. G. Hamilton^{*c*}

Received 23rd September 2009, Accepted 20th November 2009 First published as an Advance Article on the web 5th January 2010 DOI: 10.1039/b919894f

A series of enantiopure 2,2'-bipyridines have been synthesised from the corresponding *cis*-dihydrodiol metabolites of 2-chloroquinolines. Several of the resulting hydroxylated 2,2'-bipyridines were found to be useful chiral ligands for the asymmetric aminolysis of *meso*-epoxides leading to the formation of enantioenriched amino alcohols (\rightarrow 84% *ee*). *N*-oxide and *N*,*N*'-dioxide derivatives of these 2,2'-bipyridines, including separable atropisomers, have been synthesised and used as enantioselective organocatalysts in the asymmetric allylation of aldehydes to give allylic alcohols (\rightarrow 86% *ee*).

Introduction

Dioxygenase-catalysed oxidation of arene substrates provides a direct route to a wide range of enantiopure mono- and polyhydroxylated bioproducts. To date, these readily available chiral metabolites have been mainly used as synthetic precursors of a wide range of natural products.^{1a-i} In order to find alternative applications in our laboratories, several of these hydroxylated arene products have also been evaluated as synthetic precursors of chiral ligands,^{2a,b} chiral resolving agents,^{2c} chiral scaffolds^{2d} and chiral auxiliaries.^{2e} Recent studies have centred on chiral 2,2'-bipyridines derived from *cis*-dihydrodiol metabolites of quinolines, which have shown considerable potential as chiral ligands.^{2b} Anticipation that other types of 2,2'-bipyridines, including hydroxylated derivatives and *N*-oxides, could also be of value as both chiral ligands and chiral organocatalysts in other types of asymmetric synthesis, provided the main focus of the current study.

The dioxygenase-catalysed asymmetric dihydroxylation of quinoline substrates **1A–3A** to yield the corresponding enantiopure *cis*-dihydrodiol metabolites, **1B–3B** and **1C–3C** (Scheme 1) was achieved using whole cells of mutant bacterial strains including *Pseudomonas putida* (UV4) and *Sphingomonas yanoikuyae* (B8/36).^{2b,3,4} The two *cis*-dihydroxylating biocatalysts used were toluene dioxygenase (TDO, present in *P. putida* UV4) and biphenyl dioxygenase (BPDO, present in *S. yanoikuyae* B8/36). TDO, having a smaller active site, was only able to accommodate the less bulky substrates (*e.g.* **1A** and **2A**), while BPDO, with a larger active site, was able to accept a substrate having greater steric requirements (*e.g.* **3A**). The isomeric *cis*-dihydrodiols **1B–3B** and **1C–3C** were readily separated by chromatography. Catalytic hydrogenation of the major *cis*-dihydrodiols **2B** and **3B** (PtO₂/H₂) yielded the corresponding *cis*-tetrahydrodiols (**2D** and **3D**) without hydrogenolysis of the chlorine atom.^{2b,3,4} These stable *cis*-tetrahydrodiols were protected as their dioxolane derivatives (**2E–7E**) and homocoupled to give a series of chiral 2,2'-bipyridines (**2F–7F**, Scheme 1) using the previously reported method.^{2b}

The potential of the protected 2,2'-bipyridines as chiral ligands was initially evaluated using Cu(1)-catalysed asymmetric allylic oxidations, the Kharasch–Sosnosky reaction and asymmetric cyclopropanations of the corresponding alkenes as model reactions.^{2b} The encouraging results obtained, for both the asymmetric allylic oxidations (\rightarrow 97% *ee*) and cyclopropanations (\rightarrow 95% *ee*), during these preliminary studies, prompted this more extensive investigation of our chemoenzymatically-derived hydroxylated chiral 2,2'-bipyridines and their *N*-oxide derivatives on other types of asymmetric synthesis.

In this study, the potential of the quinoline *cis*-dihydrodiols (**2B** and **3B**) as synthetic precursors of an extended range of chiral 2,2'-bipyridines having (i) fully protected (**7F**, Scheme 1), (ii) partially protected (**9**, Scheme 2) or unprotected hydroxyl groups (**8**, Scheme 2) and (iii) a new range of *N*-oxides (**2I-7I**, Scheme 2) and *N*,*N*'-dioxides (**2J-7J**, Scheme 2) has been demonstrated. A comparison of the enantioselectivity values obtained using 2,2'-bipyridines **7F**, **8** and **9**, with established chiral ligands used earlier for the Sc-catalysed asymmetric aminolysis of *meso*-epoxides, has been carried out. The *ee* values obtained during the asymmetric allylation of benzaldehydes using *N*-oxides **2I-7I** and *N*,*N*'-dioxides **2J-7J** have also been compared with known asymmetric *N*-oxide and *N*,*N*'-dioxide organocatalysts.

Results and discussion

A preliminary study from these laboratories^{2b} indicated that, in the context of an asymmetric allylic oxidation of cyclohexene 10


^aSchool of Chemistry and Chemical Engineering, The Queen's University of Belfast, Belfast, UK BT9 5AG. E-mail: dr.boyd@qub.ac.uk; Fax: +44 (0) 2890975418; Tel: +44 (0) 2890975419

^bSchool of Biological Sciences, The Queen's University of Belfast, Belfast, UK BT9 5AG

^cAgri-food and Biosciences Institute for Northern Ireland, Newforge Lane, Belfast, UK BT9 5PX

[†] This paper is part of an Organic & Biomolecular Chemistry web theme issue on biocatalysis.

[‡] Electronic supplementary information (ESI) available: Further experimental methods, spectroscopic and crystallographic data. CCDC reference numbers 746347–746349. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b919894f



Scheme 1 Synthesis of *cis*-dihydrodiols (1B–3B, 1C–3C) and 2,2'-bipyridines (2F–7F).

and cycloheptene 12 (Scheme 3), the most efficient of the 2,2'bipyridine ligands 2F-6F (Scheme 1) appeared to be compound **6F** (\rightarrow 97% *ee*). However, when these ligands were evaluated using the allylic oxidation of cyclopentene, although comparable yields were obtained (ca. 50% yield), the enantioselectivity values were less promising, with the best result (38% ee) again being obtained using compound 6F. As this ligand also appeared to have the most bulky dioxolane substituents ($\mathbf{R'} = \mathbf{Me}$ and $\mathbf{R''} = tert$ -Bu), a further 2,2'-bipyridine 7F, containing the adamantylidine group (considered to be more sterically demanding than the cyclohexylidine group present in compound 5F), was synthesised from the corresponding cis-tetrahydrodiol 2D. Condensation of diol 2D with 2-adamantanone in the presence of an acid catalyst yielded the protected diol 7E. Following the standard coupling procedure (NiCl₂/Zn/Ph₃P/DMF) yielded the 2,2'-bipyridine 7F. A comparison of the results obtained during asymmetric oxidation of both cyclohexene 10 and cycloheptene 12 using the reported 2,2'-bipyridine ligands (5F and 6F),^{2b} and the new ligand (7F), is shown in Table 1.


Despite the replacement of the cyclohexylidene group in the 2,2'bipyridine **5F** by a more bulky adamantylidene group in ligand **7F**, the stereoselectivity observed in the synthesis of benzoate **11** using this ligand was either slightly less (79% vs. 85% ee using ligand **5F**) or similar (91% vs. 92% ee using ligand **5F**). Following this unsuccessful attempt to improve enantioselectivity over that found using ligands **5F** or **6F**, the effect on enantioselectivity of increasing the ligand's polarity was then examined. This was achieved by deprotection of the *bis*-acetonide **2F** (HCl/MeOH) to form the C₂-symmetric 2,2'-bipyridine tetraol **8** in acceptable yield

Table 1Absolute configuration (Ab. config.) and enantiopurity values $(\% \ ee)$ of the benzoates (11 and 13) obtained by asymmetric allylicoxidation of alkenes (10 and 12)


Alkene	Benzoate	Ligand	Ab. config.	ee (%)
10	11	5F	$1S(11_s)$	85ª
12	13	5F	$1S(13_s)$	92ª
10	11	6F	$1S(11_s)$	90 ^a
12	13	6F	$1S(13_s)$	97ª
10	11	7 F	$1S(11_s)$	79
12	13	7 F	$1S(13_{s})$	91

(80%) (Scheme 2). The new polyhydroxylated compound **8** was not found to be a suitable ligand for the allylic oxidation procedure shown in Scheme 3. Preliminary studies have, however, shown that the minor *cis*-dihydrodiol isomers (*e.g.* **2**C) can also be chemically converted into the corresponding *cis*- or *trans*-tetrahydrotetraols, protected as *bis*-acetonides and coupled. This extended the range of chemoenzymatically-derived enantiopure 2,2'-bipyridines as chiral ligands in the Kharasch–Sosnosky reaction.

Reaction of the tetraol **8** with *tert*-butyldiphenylsilyl chloride in the presence imidazole as catalyst resulted in preferential protection of the less hindered OH groups on C-7, to give 2,2'bipyridine diol **9** as the major product (45% yield) after preparative layer chromatography (PLC) purification. Earlier reports of 2,2'bipyridines bearing two OH groups adjacent to the pyridine rings, *e.g.* **14**⁵ and **15**,⁶ showed them to be excellent chiral ligands for a range of asymmetric synthesis reactions. The 2,2'-bipyridine




Scheme 2 Synthesis of 2,2'-bipyridines (8 and 9), N-oxides (2I-7I) and N,N'-oxides (2J-7J).



Scheme 3 Asymmetric allylic oxidation of alkenes 10 or 12 to benzoates 11 or 13.

diol 15 was found to be a particularly enantioselective ligand for aminolysis of epoxides yielding aminoalcohols with high *ee* values (\rightarrow 97% *ee*).⁶ The proximate OH groups appeared to be essential for the formation of the scandium–bipyridine complex, since their protection as MeO groups resulted in total loss of enantioselectivity.⁶ As each of the new chiral 2,2'-bipyridines 8 and 9 had OH groups in comparable positions to those in compounds 14 and 15, they were examined as potential ligands for the scandium-catalysed asymmetric aminolysis of *meso*-epoxides bearing phenyl (*e.g.* 16) and 2-naphthyl substituents (*e.g.* 21, Scheme 4). The aminolysis of *cis*-stilbene oxide **16** was studied using aniline **17** or *N*-methylaniline **19**, with Sc(OTf)₃ (10 mol%) as Lewis acid and the enantiopure 2,2'-bipyridines **8** or **9** (12 mol%) as ligands, in CH₂Cl₂ solvent (Scheme 4). The enantioselectivity values for the resulting aminoalcohols found using *cis*-stilbene oxide **16** and ligand **9** with aniline **17** (aminoalcohol **18**, 61% *ee*) or *N*-methylaniline **19** (aminoalcohol **20**, 68% *ee*) were encouraging (Table 2), and prompted further studies using the more sterically hindered *meso*-epoxide, *cis*-1,2-bis-(2-naphthyl)ethane oxide **21**. Thus, using aniline **17** and ligand **9** with this epoxide (**21**) under similar conditions [Sc(OTf)₃, CH₂Cl₂], the resulting aminoalcohol product **22** was obtained with a higher *ee* value (84%) compared with that obtained earlier (82% *ee*) using ligand **14**.⁶ The optimal enantioselectivity obtained by Schneider *et al.* was found in the synthesis of aminoalcohols **20** (\rightarrow 97% *ee*) using ligand **14**.⁶

The presence of hydroxyl groups in ligand **8**, while necessary for complexation with the scandium atom and the resulting enantioselectivity, also increased its water-solubility, a property which was further utilised. A recent literature report⁷ showed that ligand **14** and a 1.2 mol% loading of scandium–bipyridine complex with dodecyl sulfate counterion Sc(OSO₃C₁₂H₂₅)₃ in water, was sufficient to catalyse the asymmetric aminolysis of epoxide **16** (using amine **17**) yielding aminoalcohol **18** (91% *ee*). This was used as a precedent for a preliminary study of ligands **8** and **9** under



Scheme 4 Asymmetric aminolysis of *meso*-epoxides 16 and 21.

Table 2 Asymmetric aminolysis of epoxides 16 and 21 using amines 17 and 19, ligands 8 and 9, and $Sc(OTf)_3$ in CH_2Cl_2 solvent


Epoxide	Amine	Ligand	Product (% yield)	Absolute configuration	ee (%)
16	17	9	18 (64)	15,25	61
16	19	9	20 (48)	1S, 2S	68
16	17	8	$18(50)^a$	1S, 2S	57ª
21	17	9	22 (77)	1S, 2S	84
21	17	8	22 $(43)^a$	15,25	62ª
" Using li	gand 8 (1	.2 mol%),	$Sc(OSO_3C_{12}H_{25})_3$ and	d water as solve	nt.

similar conditions (Table 2). The enantioselectivity values found during the formation of aminoalcohols **18** (57% *ee*) and **22** (62% *ee*) under aqueous conditions were only moderate in comparison to those reported earlier (\rightarrow 96% ee).⁷ The unoptimised results shown in Table 2 in either CH₂Cl₂ (\rightarrow 84% *ee*) or water (\rightarrow 62% *ee*) do, however, indicate the potential of these new polyhydroxylated chiral 2,2'-bipyridines, **8** and **9**, as chiral ligands for the asymmetric aminolysis of *meso*-epoxides.

The second part of this study involved the peroxyacid oxidation of the chiral 2,2'-bipyridines **2F**–**7F** to give the corresponding *N*-oxides **2I**–**7I** and *N*,*N*'-dioxides **2J**–**7J** (Scheme 2), and an evaluation of the potential of these new 2,2'-bipyridine *N*-oxide derivatives as Lewis bases and enantioselective organocatalysts for the asymmetric allylation of aldehydes **23**, **25**, and **27** (the Sakuri–Hosomi reaction,^{8a-d} Scheme 5). Mono-*N*-oxidation of the 2,2'-bipyridines **2F**–**7F** to yield the corresponding 2,2'-bipyridine *N*-oxides **2I**–**7I** was mainly observed using one equivalent of MCPBA in CH₂Cl₂ at 0 °C (54–72% yield). A lower yield of *N*-oxide **3I** (40%) was found when using the most hindered 2,2'-bipyridine **3F**. In all cases, the major *N*-oxide products (**2I**–**7I**) were readily separated from the minor amounts of *N*,*N*'-dioxides (**2J**–**7J**) and unreacted 2,2'-bipyridine by column chromatography. Using an excess of MCPBA, the 2,2'-bipyridine *N*,*N*'-dioxides **2J**–**7J** were generally isolated as the major products in higher yields (70–80%), with the exception of the more hindered *N*,*N*'-dioxide **3J** (52%), where the reaction again proved to be much slower.

¹H-NMR analysis indicated that all of the *N*-oxides and *N*,*N'*-dioxides were single compounds, except for those bearing Me groups at C-7 and C-7', *i.e. N*-oxide **3I** and the *N*,*N'*-dioxide **3J**, which were found to exist as mixtures of atropisomers, *i.e.* **3I**_{*P*} : **3I**_{*M*} (3 : 1) and **3J**_{*P*} : **3J**_{*M*} (8 : 1). While these atropisomeric pairs were each found to be separable by multi-elution PLC, they also appeared to be configurationally unstable, with total equilibration occurring spontaneously at room temperature in CDCl₃ solution over a period of three weeks ($t_{1/2} > 2$ d). However, the major isomer in each case (**3I**_{*P*} and **3J**_{*P*}) could be isolated in pure form by recrystallisation. In order to confirm their structures, and preferred conformations/configurations, X-ray crystallographic analysis was carried out on the 2,2'-bipyridine *N*-oxide **3I**_{*P*} (Fig. 1) and *N*,*N'*-dioxides **2J** (Fig. 2), and **3J**_{*P*} (Fig. 3).

In the crystalline state, the parent 2,2'-bipyridine **2F** was earlier shown to have the two pyridine rings almost co-planar



Scheme 5 Asymmetric allylation of aldehydes 23, 25, and 27 using N-oxides 21–7I and N, N'-dioxides 2J–7J as organocatalysts.




Fig. 1 X-Ray crystal structure of compound $3I_{P}$.




Fig. 2 X-Ray crystal structure of compound 2J.




Fig. 3 X-Ray crystal structure of compound $3J_P$.

(N–C–C′–N′ torsional angle of 173°), with the two N atoms adopting a conjugated *transoid* conformation.^{2b} Conversely, the preferred conformation within the 2,2′-bipyridine-*N*,*N*′-dioxide **2J** crystal structure was found to have the pyridine rings approaching the orthogonal (N–C–C′–N′ torsional angles of +67° and +68° for two independent molecules, Fig. 2); *i.e.* all molecules have helicity *P*. The major *N*-oxide atropisomer **3I**_{*P*}, crystallised from the mixture of atropisomers (**3I**_{*P*}/**3I**_{*M*}), consisted of two crystallographically independent molecules that did not differ significantly in preferred conformation (Fig. 1). Thus the pyridine rings were again almost orthogonal (N–C–C′–N′ torsional angles of +117° and +108°), *i.e.* all molecules have helicity *P* but, unlike compound **2J**, are closer to *transoid* than *cisoid*.

The crystal structure of the N,N'-dioxide $3J_P$ was isomorphous with the *N*-oxide $3I_P$, *i.e.* it showed two crystallographically independent molecules with N–C–C'–N' torsion angles of +112° and +107°, and helicity *P* (Fig. 3). It was evident from the formation and separation of the atropisomers $3I_P/3I_M$ and $3J_P/3J_M$ (and the absence of atropisomers from compound **2J**), and possibly also from the preferred conformations in the crystalline state, that the major steric interactions are found between the two Me groups on C-3 with the O atoms on each of the *N*-oxide groups playing a relatively minor role.

Earlier literature reports have shown that both *N*-oxide (*e.g.* **29** or **30**)^{9*a*-*c*} and *N*,*N'*-dioxide derivatives (*e.g.* **31**)^{10*a*-*d*,11,12} of chiral 2,2'-bipyridines are efficient chiral organocatalysts for the asymmetric allylation of some aldehydes (\rightarrow 97% *ee*).

The potential of *N*-oxides **2I**, **3I**_{*P*} and **4I**–**7I**, and *N*,*N'*-dioxides **2J**, **3J**_{*P*} and **4J**–**7J** as catalysts for asymmetric allylation was evaluated using similar conditions, *i.e.* allyltrichlorosilane, tetrabutylammonium iodide, diisopropylethylamine and benzaldehyde **23**, 4-chlorobenzaldehyde **25** and 4-methoxybenzaldehyde **27** (Tables 3 and 4). As found in the earlier studies with ligands **29–31**,^{9–12} the rate of the allylation reaction was slower when using the *N*-oxides, and thus, these reactions were carried out at higher temperatures (0 °C or –40 °C) compared with the corresponding *N*,*N'*-dioxides (–78 °C). When the *N*-oxides **2I**, **3I**_{*P*} and **4I–7I** were




Table 3 Asymmetric allylation of aldehydes **23**, **25** and **27** to yield allylic alcohols **24**, **26** and **28**, using allyltrichlorosilane and the *N*-oxide ligands **2I–7I** in CH_2Cl_2 after 24 h


Aldehyde	Catalyst	Product (% yield)	Temp./°C	Absolute configuration	ee (%)
23	21	24 (60)	0	R	35
25	2I	26 (65)	0	R	46
27	2I	28 (72)	0	R	63
27	$3I_P$	$28(41)^{a}$	-40	R	86
23	4I	24 $(42)^a$	-40	R	24
27	4I	28 $(35)^a$	-40	R	67
23	5I	24 $(28)^a$	-40	R	30
27	5I	28 $(39)^a$	-40	R	81
27	6I	28 $(21)^a$	-40	R	56
27	7I	28 $(46)^a$	-40	R	60

Table 4Asymmetric allylation of aldehydes 23, 25 and 27 to yield allylicalcohols 24, 26 and 28, using allyltrichlorosilane and the N,N'-dioxideligands 2J-7J in CH₂Cl₂ after 12 h

Aldehyde	Catalyst	Product (% yield)	Temp./°C	Absolute configuration	ee (%)
23	2J	24 (64)	-78	R	26
25	2J	26 (61)	-78	R	31
27	2J	28 (75)	-78	R	80
27	$3J_P$	28 $(68)^a$	-78	R	59
23	4J	24 (62)	-78	R	16
27	5J	28 (71)	-78	R	73
23	5J	24 (28)	-78	R	14
27	6J	28 (45)	-78	S	71
27	6J	28 (63)	-78	R	72
27	7J	28 (44)	-78	R	73

used, the reactions were incomplete after 24 h at -40 °C, and thus, yields were lower (21–46%, Table 3).

However, with N,N'-dioxides 2J, 3J_P and 4J–7J, the reactions went to completion (28–75% yields, Table 4) when the allylation reactions were conducted at –78 °C. Similarly, as found earlier, the optimal results were obtained using 4-methoxybenzaldehyde 27 with either the *N*-oxides 2I, 3I_P, 4I–7I (56–86% *ee*) or the N,N'-dioxides 2J, 3J_P, 5J–7J (59–80% *ee*), compared to those obtained using benzaldehyde 23 (24–35% *ee* and 14–26% *ee*). It is noteworthy that the highest degree of enantioselectivity (86% *ee*) was observed using aldehyde 27 and the *N*-oxide atropisomer 3I_P (Table 3). This observation is similar to that found using the N,N'dioxide 31 during allylation of 4-methoxybenzaldehyde 27 where the product alcohol 28 was also found to have the highest *ee* value (92%) compared with other substituted aldehydes (R = H, CF₃).¹² Unfortunately, the additional presence of stereogenic chirality of



the *N*,*N*'-dioxide atropisomer $3J_P$ did not assist during allylation of aldehyde 27, when lower enantioselectivity was found (59% *ee*, Table 4). In view of the recent proposal that two plausible reaction mechanisms could be used in the context of asymmetric allylation reactions using different *N*,*N*'-dioxide ligands and 4-substituted aldehydes,¹⁰⁶ we have not attempted to further rationalise the range of *ee* values obtained herein. Since the reactions in CH₂Cl₂ with compounds $3I_P$ and $3J_P$ were carried out at low temperature (–40 or –78 °C respectively), and as the atropisomers were only found to interconvert very slowly at room temperature ($t_{1/2} > 2$ d in CDCl₃), it is unlikely that any significant degree of atropisomerization had occurred during the asymmetric allylation reactions.

The allylic alcohol products were generally found to have a marked preference for the (R) absolute configuration $(24_R, 26_R)$ and 28_R) regardless of the nature of the aldehyde or ligand substituents. The only exception being aldehyde 27 and N-oxide ligand 6J where the product 28 had an excess of the (S) enantiomer (71% ee). A recent study^{10c} has shown that a change in solvent can have a dramatic effect on the preferred absolute configurations of the alcohol products obtained using atropisomeric 2,2'-bipyridine-N-oxides as organocatalysts for the asymmetric allylation of benzaldehydes. Although the optimal ee values of products obtained using the sixteen new chiral 2,2'-bipyridines, 2,2'-bipyridine N-oxides or N,N'-dioxides during the present study were found to be in the range 80-91% (Tables 1-4), it should be emphasised that optimisation studies have yet to be carried out. Having demonstrated the value of cis-dihydrodiols 2B and 3B as synthetic precursors of chiral ligands,^{2b} chiral scaffolds^{2d} and now chiral organocatalysts, efforts to find and develop more efficient dioxygenase biocatalysts to produce these compounds, without the formation of other cis-dihydrodiol isomers, are currently in progress.

Conclusions

In conclusion, the current report has shown that:

(i) the major enantiopure *cis*-dihydrodiol metabolites from 2-chloroquinoline (**2B**) and 3-methyl-2-chloroquinoline (**3B**) can be used as precursors in the synthesis of a new range of 2,2'-bipyridine ligands. These include ligands with: (a) fully protected hydroxyl groups (**2F**–**7F**), (b) free hydroxyl groups (**8** and **9**), and the corresponding *N*-oxides (**2I**–**7I**) and *N*,*N*'-dioxides (**2J**–**7J**).

(ii) the hydroxylated 2,2'-bipyridine ligands (8 and 9) can be applied as chiral ligands in the asymmetric aminolysis of *meso*-epoxides (16 and 21), leading to the formation of enantioenriched amino alcohols (18, 20 and $22 \rightarrow 84\%$ ee).

(iii) the preferred conformations and configurations of 2,2'bipyridine N-oxide (2I–7I) and N,N'-dioxide (2J–7J) derivatives (including the separable atropisomeric pairs $3I_P/3I_M$ and $3J_P/3J_M$) have been assigned by X-ray crystallography and NMR spectroscopy.

(iv) the *N*-oxide and *N*,*N'*-dioxide derivatives (21–71, 2J–7J), can be utilised as enantioselective organocatalysts in the asymmetric allylation of aldehydes to give allylic alcohols (24, 26 and 28, \rightarrow 86% *ee*).

(v) the remarkable enantioselectivity initially introduced through biocatalysis can now be transferred (*via* chemoenzymatic synthesis) to homogeneous catalysis and organocatalysis.

Experimental

NMR (¹H and ¹³C) spectra were recorded on Bruker Avance DPX-300 and DPX-500 instruments and mass spectra were run at 70 eV, on a VG Autospec Mass Spectrometer, using a heated inlet system. Accurate molecular weights were determined by the peak matching method, with perfluorokerosene as the standard. Elemental microanalyses were carried out on a PerkinElmer 2400 CHN microanalyser. For optical rotation ($[\alpha]_D$) measurements (*ca.* 20 °C, 10⁻¹ deg cm² g⁻¹), a PerkinElmer 341 polarimeter was used.

Flash column chromatography and PLC were performed on Merck Kieselgel type 60 (250-400 mesh) and $PF_{254/366}$ respectively. Merck Kieselgel type $60F_{254}$ analytical plates were used for TLC.

The 2,2'-bipyridine ligands 2F-6F were obtained using the reported method^{2c} and were supplemented by samples available from earlier studies in these laboratories.

Biotransformations of 2-chloroquinoline 2A and 2-chloro-3-methyl-quinoline 3A

Biotransformation of 2-chloroquinoline **2A** (100 g, 0.61 mol) was carried out using *P. putida* UV4 in a New Brunswick Scientific Bioflo 5000, 1201 fermentor and the previously reported method.⁴ The crude bioproduct mixture was obtained by concentration of the aqueous culture medium under reduced pressure followed by repeated EtOAc extraction. The required (less polar) *cis*-dihydrodiol **2B** (24.5 g, 21%, R_f 0.3 in 7% MeOH in CHCl₃); [α]_D +146, MeOH) was separated from the minor *cis*-dihydrodiol **2C** (10.1 g, 8.5%, R_f 0.45); [α]_D +136, MeOH) by flash column chromatography of the crude mixture on silica gel (5% EtOAc in hexane \rightarrow 10% MeOH in EtOAc). Biotransformation of 2-chloro-3-methylquinoline **3A** (0.2 g, 1.13 mmol) using *P. putida* UV4 under similar conditions resulted in >90% of the substrate being recovered and the production of several unidentified metabolites in very low yields.

The biotransformation of 2-chloro-3-methylquinoline **3A** (10.0 g, 0.056 mol) was repeated using *S. yanoikuyae* B8/36 and the conditions reported earlier.^{2b,d} The major and less polar dihydrodiol **3B** (4.2 g, 35%, R_f 0.31 in 7% MeOH in CHCl₃); $[\alpha]_D$ +184, MeOH) was separated from the minor isomer **3C** (3.0 g, 25%, R_f 0.46); $[\alpha]_D$ +172, MeOH by a combination of flash column chromatography and PLC. Dihydrodiols **2B**, **2C**, **3B** and **3C** were found to be identical to authentic samples.^{2d,3}

(3a*S*,9b*R*)-8-Chloro-3a,4,5,9b-tetrahydrospiro[1,3]dioxolo[4,5*h*]quinoline-2,2-adamantane 7E

A mixture of *cis*-diol **2D** (1.5 g, 7.5 mmol), *p*-toluenesulfonic acid monohydrate (50 mg, 0.26 mmol) and 2-adamantanone (2.8 g, 18.75 mol) in benzene (50 ml) was heated at reflux using a Dean–

Stark trap for 20 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (50 ml), then washed with a saturated aqueous solution of NaHCO₃ (10 ml). The organic solution was dried (Na₂SO₄) and the solvent removed under reduced pressure. The crude acetal 7E obtained was purified by column chromatography (50% EtOAc-hexane) to yield a white crystalline compound (1.9 g, 76%); mp 98 °C (from EtOAchexane); $[\alpha]_{\rm D}$ +78 (c 0.55, CHCl₃); HRMS (EI) Found: M⁺ 331.1311, $C_{19}H_{22}CINO_2$ requires 331.1339; δ_H (300 MHz, CDCl₃) 1.26-2.12 (16 H, m, adamantyl protons, H-4, H-4'), 2.53 (1H, ddd, J_{5,4'} 4.2, J_{5,4} 4.2, J_{5,5'} 15.9, H-5), 2.98 (1H, ddd, J_{5',4} 3.9, J_{5',4'} 12.0, J_{5',5} 15.6, H-5'), 4.67 (1 H, m, H-3a), 5.14 (1 H, d, J_{9b,3a} 6.3, H-9b), 7.20 (1 H, d, $J_{7,6}$ 8.0, H-7), 7.42 (1 H, d, $J_{6,7}$ 8.0, H-6); $\delta_{\rm C}$ (125 MHz, CDCl₃) 23.66, 27.33, 27.42, 28.45, 34.71, 35.25, 35.34, 35.61, 35.78, 37.56, 38.59, 73.33, 75.64, 112.05, 123.92, 133.52, 139.31, 149.47, 155.42; MS m/z (EI) 331 (M⁺, ³⁵Cl, 84%), 333 $(M^+, {}^{37}Cl, 23\%), 165 (100), 181 (97), 150 (66), 128 (38), 79 (63),$ 67 (21).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-8,8'-bis{Spiro[[1,3]dioxolo[4,5h]quinoline-2,2' adamantane]} 7F

To a stirred solution of nickel(II) chloride hexahydrate (1 g, 4.2 mmol) and triphenylphosphine (PPh₃) (3.64 g, 13.8 mmol) in dry, degassed dimethylformamide (10 ml) was added zinc powder (0.68 g, 10.2 mmol). The reaction mixture was heated at 60 °C for 1 h; the colour of the solution changed to red. A solution of acetal 7E (1 g, 3 mmol), in dry degassed dimethylformamide (10 ml), was then added and the mixture was heated at 60 °C for 5 h; it was allowed to cool to room temperature and then poured into an aqueous solution of NH₄OH (10% w/w, 20 ml). The resultant mixture was extracted with dichloromethane $(3 \times 20 \text{ ml})$. The combined extracts were washed with brine, dried (Na₂SO₄), and concentrated to afford the crude product. Purification by column chromatography (50% EtOAc-hexane) gave bipyridine 7F as a white crystalline solid (0.51 g, 58%); mp 289-290 °C (from CHCl₃-MeOH); $[\alpha]_{D}$ +210 (*c* 0.98, CHCl₃); Found: C, 76.8; H, 7.7; N, 4.7; C₃₈H₄₄N₂O₄ requires C, 77.0; H, 7.5; N, 4.7; δ_H (300 MHz, CDCl₃) 1.26-1.69 (30H, m, 2 × adamantyl protons, H-4, H-4'), 2.17 (2H, m, H-4", H-4""), 2.63 (2H, ddd, J_{5,4"} 3.9, J_{5,4} 3.9, J_{5,5"} 15.6, H-5, H-5'), 3.04 (2H, ddd, *J*_{5",4} 3.6, *J*_{5",4"} 11.7, *J*_{5",5} 15.6, H-5", H-5"'), 4.69 (2H, m, H-3a, H-3a'), 5.24 (2H, d, J_{9b.3a} 6.6, H-9b, H-9b'), 7.53 (2H, d, $J_{6,7}$ 8.1, H-6, H-6'), 8.32 (2H, d, $J_{7,6}$ 8.1, H-7, H-7'); $\delta_{\rm C}$ (125 MHz, CDCl₃) 24.40, 27.39, 27.49, 28.92, 34.93, 35.32, 35.41, 35.62, 35.96, 37.62, 38.56, 73.91, 76.54, 111.74, 121.09, 134.70, 137.13, 153.98, 155.15; MS *m*/*z* (ES) 593 (M⁺ + H, 100%).

(7*S*,8*R*,7'*S*,8'*R*)-5,6,7,8,5',6',7',8'-Octahydro-[2,2']biquinolinyl-7,8,7',8'-tetrol 8

A solution of acetonide **2F** (0.5 g, 1.22 mmol) in MeOH (6 ml) was treated with HCl solution (1.5 M, 2 ml) and the reaction mixture heated at 50 °C. When the starting material had reacted completely (3–4 h), the mixture was made alkaline by the addition of NH₄OH solution. The solvents were removed under reduced pressure and the crude product kept *in vacuo* at 50–60 °C until all the NH₄Cl salt sublimed off. Tetraol **8** was obtained as a white crystalline solid (0.3 g, 80%); mp 170–172 °C (from CHCl₃–MeOH); $[\alpha]_D$ +67 (*c* 0.5, MeOH); HRMS (ES) (Found: M⁺+H, 329.1417. C₁₈H₂₁N₂O₄

requires 329.1423); $\delta_{\rm H}$ (500 MHz, CD₃OD) 1.98 (2H, m, H-6, H-6'), 2.28 (2H, m, H-6'', H-6''), 2.78 (2H, ddd, $J_{5,6}$ 2.5, $J_{5,6''}$ 6.4, $J_{5,5''}$ 17.0, H-5, H-5'), 3.12 (2H, ddd, $J_{5',6}$ 6.4, $J_{5'',6''}$ 10.9, $J_{5'',5}$ 17.0, H-5'', H-5'''), 4.42 (2H, m, H-7, H-7'), 4.68 (2H, d, $J_{8,7}$ 3.0, H-8, H-8'), 7.58 (2H, d, $J_{4,3}$ 8.0, H-4, H-4'), 8.23 (2H, d, $J_{3,4}$ 8.0, H-3, H-3'); $\delta_{\rm C}$ (125 MHz, CDCl₃) 23.73, 25.66, 66.93, 71.02, 120.131, 131.81, 137.79, 153.29, 154.69; MS m/z (ES) 329 (M⁺+H, 100%), M⁺ 328 (12).

(7*S*,8*R*,7'*S*,8'*R*)-7,7'-Di(1-(*tert*-butyl)-1,1-diphenylsilyloxy)-5,6,7,8,5',6',7',8'-octahydro[2,2']biquinolinyl-8,8'-diol 9

To a stirred solution of tetrol 8 (0.3 g, 0.9 mmol) and imidazole (0.34 g, 5 mmol), in dry DMF (5 ml) maintained at 0 °C under nitrogen, was added, dropwise over 20 min, tert-butyldiphenylsilyl chloride (0.3 ml, 1.09 mmol). The reaction mixture was stirred for 4 h at room temperature, diluted with dichloromethane (75 ml) and the solution washed with water. The organic layer was dried (Na_2SO_4) , the solvent evaporated, and the crude product purified by PLC (20% EtOAc in hexane). The disilyl derivative 9 was obtained as a white solid (0.33 g, 45%); mp 74 °C (from EtOAc-hexane); $[\alpha]_D$ -38 (c 0.72, CHCl₃); HRMS (ES) (Found: M⁺+H, 807.3960. $C_{50}H_{57}N_2O_4Si_2$ requires 807.4014); δ_H $(500 \text{ MHz}, \text{CDCl}_3, \text{D}_2\text{O} \text{ exchange}) 1.01 [18\text{H}, \text{s}, 2 \times \text{C}(\text{Me})_3], 1.75$ (2H, m, H-6, H-6'), 1.99 (2H, m, H-6", H-6"'), 2.68 (2H, ddd, J_{5,6} 6.1, *J*_{5,6"} 6.1, *J*_{5,5"} 17.2, H-5, H-5'), 3.02 (2H, ddd, *J*_{5",6} 7.2, *J*_{5",6"} 7.2, J_{5".5} 17.2, H-5", H-5"'), 4.40 (2H, m, H-7, H-7'), 4.68 (2H, d, J₈₇ 3.0, H-8, H-8'), 7.18-7.34 (12H, m, ArH), 7.46 (2H, d, J 8.0, ArH); 7.62 (4H, m, ArH), 7.71 (4H, m, ArH), 8.25 (2H, d, J 8.0, ArH); $\delta_{\rm C}$ (125 MHz, CDCl₃) 19.41, 24.74, 26.20, 26.57, 26.98, 70.57, 72.13, 119.92, 127.45, 127.61, 127.76, 129.53, 129.60, 129.68, 131.52, 133.90, 134.31, 134.80, 135.93, 137.02, 153.19, 154.62; MS m/z (ES) 807 (M⁺+H, 30%), 806 (M⁺, 68%).

General procedure for the synthesis of N-oxides

m-Chloroperoxybenzoic acid (MCPBA, 50–55%, 1.1 equiv.) was added, in small portions, to a stirred solution of bipyridine (1 mmol) in dichloromethane (20 ml) at 0 °C, and the stirring continued at 0 °C for a further 4 h. The reaction mixture was washed, successively, with a saturated Na₂SO₃ solution, Na₂CO₃ solution and finally with water. The organic layers were dried (Na₂SO₄), concentrated under reduced pressure, and the residue purified by column chromatography (10% MeOH in CHCl₃) to give the corresponding *N*-oxide as a white crystalline solid. This purification method was followed for all the *N*-oxides.

(3a*S*,9b*R*,3a'*S*,9b'*R*)-2,2,2',2'-Tetramethyl-3a,4,5,9b,3a',4',5',9b'octahydro-[8,8']bi[[1,3]-dioxolo[4,5*h*]quinolinyl] *N*-oxide 2I

Bipyridine **2F** (0.5 g, 1.22 mmol) gave *N*-oxide **2I** (0.3 g, 60%); mp 201–202 °C (from CHCl₃–MeOH); $[\alpha]_D +215$ (*c* 1.0, CHCl₃); HRMS (EI) (Found: M⁺, 424.2011. C₂₄H₂₈N₂O₅ requires 424.1998); δ_H (300 MHz, CDCl₃) 1.37 (3H, s, Me), 1.39 (3H, s, Me), 1.49 (3H, s, Me), 1.52 (3H, s, Me), 1.75 (2H, m, H-4, H-4'), 2.23 (2H, m, H-4", H-4"), 2.61 (2H, m, H-5, H-5'), 3.04 (2H, m, H-5", H-5"), 4.74 (2H, m, H-3a, H-3a'), 5.23 (1H, d, $J_{9b,3a}$ 7.0, H-9b'), 5.75 (1H, d, $J_{9b,3a}$ 7.0, H-9b), 7.10 (1H, d, *J* 8.1, Ar), 7.55 (1H, d, *J* 8.1, Ar), 8.21 (1H, d, *J* 8.4, Ar), 8.91 (1H, d, *J* 8.1, Ar); δ_C (125 MHz, CDCl₃) 23.42, 23.73, 24.73, 25.23, 26.81, 26.84, 27.14,

28.14, 69.87, 72.77, 73.78, 76.31, 108,37, 108.85, 125.27 (2C), 126.75, 134.87, 136.09, 137.16, 145.65, 145.70, 148.38, 153.24; MS m/z (EI) 424 (M⁺, 45%), 408 (34).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-2,2,7,2',2',7'-Hexamethyl-3a,4,5,9b,3a',4',5',9b'-octahydro-[8,8']bi[[1,3]dioxolo[4,5*h*]quinolinyl]*N*-oxide 3I_P

The oxidation of bipyridine 3F (0.3 g, 0.7 mmol) with MCPBA yielded *N*-oxide **3I** as a mixture of atropisomers $3I_P : 3I_M$ (3:1). These were separated by multi-elution PLC (EtOAc) to afford the major N-oxide (+)- $3I_P$ (0.09 g, 30%); mp 266–268 °C (from EtOAc–MeOH); $[\alpha]_D$ +104 (c 0.66, CHCl₃); HRMS (EI) (Found: M⁺, 452.2313. $C_{26}H_{32}N_2O_5$ requires 452.2311); δ_H (300 MHz, CDCl₃) 1.32 (3H, s, Me), 1.36 (3H, s, Me), 1.42 (3H, s, Me), 1.46 (3H, s, Me), 1.82 (2H, m, H-4, H-4'), 2.05 (3H, s, ArMe), 2.21 (5H, m, ArMe, H-4", H-4""), 2.58 (2H, m, H-5, H-5'), 3.00 (2H, m, H-5", H-5""), 4.66 (2H, m, H-3a, H-3a'), 5.19 (1H, d, J_{9'b,3a} 6.5, H-9b'), 5.63 (1H, d, J_{9b,3a} 6.9, H-9b), 6.98 (1H, s, H-6'), 7.39 (1H, s, H-6); $\delta_{\rm C}$ (125 MHz, CDCl₃) 17.89, 19.06, 23.60, 24.02, 25.36, 25.47, 27.34, 27.40, 27.63, 28.07, 108.60, 109.13, 127.47, 133.53, 134.59, 135.31, 136.91, 138.51, 143.14, 147.06, 150.08, 152.40; MS m/z (EI) 452 (M⁺, 18%), 436 (100), 424 (13). Minor atropisomer $3I_M$. δ_H (300 MHz, CDCl₃) 1.25 (3H, s, Me), 1.29 (3H, s, Me), 1.33 (3H, s, Me), 1.38 (3H, s, Me), 1.75 (2H, m, H-4, H-4'), 1.82 (3H, s, ArMe), 1.95 (3H, m, ArMe), 2.05(2H, m, H-4", H-4""), 2.48 (2H, m, H-5, H-5'), 2.91 (2H, m, H-5", H-5""), 4.60 (2H, m, H-3a, H-3a'), 5.07 (1H, d, J_{9'b,3a} 6.6, H-9b'), 5.573 (1H, d, J_{9b,3a} 6.6, H-9b), 6.86 (1H, s, H-6'), 7.30 (1H, s, H-6).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-2,2,2',2'-Tetraethyl-3a,4,5,9b,3a',4',5',9b'octahydro-[8,8']bi[[1,3]-dioxolo[4,5*h*]quinolinyl] *N*-oxide 4I

Bipyridine **4F** (1 g, 2.15 mmol) gave *N*-oxide **4I** (0.74 g, 72%); mp 139 °C (from EtOAc–MeOH); $[\alpha]_D + 276 (c 1.08, CHCl_3)$; (Found: C, 69.8; H, 7.5; N, 5.7. C₂₈H₃₆N₂O₅ requires C, 70.0; H, 7.55; N, 5.8%); δ_H (500 MHz, CDCl₃) 0.73 (6H, m, $2 \times CH_2Me$), 1.02 (6H, m, $2 \times CH_2Me$) 1.62 (4H, m, $2 \times CH_2Me$), 1.58-1.83 (6H, m, $2 \times CH_2Me$) 1.62 (4H, m, $2 \times CH_2Me$), 1.58-1.83 (6H, m, $2 \times CH_2Me$), 1.31 (2H, m, H-5", H-5"), 4.73 (2H, m, H-3a, H-3a'), 5.23 (1H, d, $J_{9b,3a}$ 6.8, H-9b'), 5.75 (1H, d, $J_{9b,3a}$ 6.8, H-9b), 7.13 (1H, d, *J* 8.2, Ar*H*), 7.54 (1H, d, *J* 8.2, Ar*H*), 8.19 (1H, d, *J* 8.2, Ar*H*), 8.86 (1H, d, *J* 8.2, Ar*H*); δ_C (125 MHz, CDCl₃) 7.74, 7.94, 9.18, 23.45, 23.74, 27.15, 27.94, 29.25, 29.53, 29.91, 30.04, 50.90, 70.45, 72.94, 73.86, 76.61, 112.82, 113.01, 125.16, 125.81, 127.25, 134.86, 136.44, 137.49, 146.02, 146.54, 148.77, 154.15; MS *m/z* (EI) 480 (M⁺, 5%), 435 (20), 379 (24), 293 (35), 277 (100), 199 (25), 85 (53), 71 (62).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-8,8'-bis{Spiro[[1,3]dioxolo[4,5h]quinoline-2,1'-cyclohexane]} *N*-oxide 5I

Bipyridine **5F** (1 g, 2 mmol) yielded *N*-oxide **5I** (0.67 g, 65%); mp 246 °C (from CHCl₃–MeOH); $[\alpha]_D$ +226 (*c* 1.09, CHCl₃); (Found: C, 71.1; H, 7.0; N, 5.5. C₃₀H₃₆N₂O₅ requires C, 71.4; H, 7.2; N, 5.6%); δ_H (300 MHz, CDCl₃) 1.54-1.75 (22H, m, 2×(CH₂)₅, H-4, H-4'), 2.25 (2H, m, H-4", H-4"), 2.59 (2H, m, H-5, H-5'), 3.04 (2H, m, H-5", H-5"), 4.73 (2H, m, H-3a, H-3a'), 5.22 (1H, d, $J_{9'b,3a}$ 6.6, H-9b'), 5.75 (1H, d, $J_{9b,3a}$ 6.6, H-9b), 7.16 (1H, d, *J* 8.4, Ar*H*), 7.54 (1H, d, *J* 7.8, Ar*H*), 8.16 (1H, d, *J* 8.1, Ar*H*), 8.85

(1H, d, J 8.1, ArH); δ_c (125 MHz; CDCl₃) 22.96, 24.30, 24.67, 25.01, 25.34, 25.72, 27.25, 28.64, 34.66, 35.23, 36.79, 37.49, 69.77, 72.72, 73.59, 75.85, 109.87, 110.32, 125.49, 125.87, 126.88, 135.39, 136.43, 137.64, 146.15, 146.45, 148.92, 154.13; MS *m*/*z* (EI) 504 (M⁺, 2%), 256 (38), 375 (28), 293 (23), 488 (10).

(2*S*,3a*S*,9b*R*,2'*S*,3a'*S*,9b'*R*)-2,2'-di-*tert*-Butyl-3a,4,5,9b,3a',4',5',9b'-octahydro-2,2'-dimethyl-[8,8']bi[[1,3]dioxolo[4,5*h*]quinolinyl]*N*-oxide 6I

Bipyridine **6F** (1 g, 1.96 mmol) formed *N*-oxide **6I** (0.7 g, 68%); mp 236 °C (from EtOAc–hexane); $[\alpha]_D + 262 (c 1.16, CHCl_3)$; HRMS (ES) (Found: M⁺+H, 509.3022. C₃₀H₄₁N₂O₅ requires 509.3015); δ_H (300 MHz, CDCl_3) 0.87 [9H, s, C(Me)_3], 0.88 [9H, s, C(Me)_3], 1.43 (3H, s, Me), 1.46 (3H, s, Me), 1.78 (2H, m, H-4, H-4'), 2.34 (2H, m, H-4", H-4"), 2.56 (2H, m, H-5, H-5'), 3.09 (2H, m, H-5", H-5"), 4.78 (2H, m, H-3a, H-3a'), 5.24 (1H, d, $J_{9b,3a}$ 7.1, H-9b'), 5.75 (1H, d, $J_{9b,3a}$ 6.9, H-9b), 7.06 (1H, d, J 8.4, ArH), 7.51 (1H, d, J 8.1, ArH), 8.21 (1H, d, J 8.2, ArH), 8.90 (1H, d, J 8.1, ArH); δ_C (125 MHz, CDCl₃) 17.83, 18.14, 23.46, 23.63, 25.26, 25.31, 26.69, 27.65, 38.14, 38.19, 69.65, 72.07, 73.02, 75.85, 113.25, 113.51, 124.56, 125.00, 126.73, 134.36, 136.10, 136.98, 145.60, 145.81, 148.58, 153.61; MS *m*/*z* (ES) 509 (M⁺ + H, 75%).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-8,8'-bis{Spiro[[1,3]dioxolo[4,5*h*]quinoline-2,2'adamantane]} *N*-oxide 7I

Bipyridine **7F** (0.5 g, 0.8 mmol) yielded *N*-oxide **7I** (0.28 g, 54%); mp 295 °C (decomp.; from CHCl₃–EtOAc); $[\alpha]_D$ +237 (*c* 0.74, CHCl₃); HRMS (ES) (Found: M⁺+ H, 609.3356. C₃₈H₄₅N₂O₅ requires 609.3328); δ_H (300 MHz, CDCl₃) 1.51-2.04 (30H, m, 2 × adamantyl protons, H-4, H-4'), 2.23 (2H, m, H-4", H-4"'), 2.58 (2H, m, H-5, H-5'), 3.04 (2H, m, H-5", H-5"'), 4.69 (2H, m, H-3a, H-3a'), 5.20 (1H, d, $J_{9'b,3a}$ 6.5, H-9b'), 5.75 (1H, d, $J_{9b,3a}$ 6.5, H-9b), 7.08 (1H, d, *J* 8.2, Ar*H*), 7.53 (1H, d, *J* 8.1, Ar*H*), 8.07 (1H, d, *J* 8.2, Ar*H*), 8.71 (1H, d, *J* 8.1, Ar*H*); δ_C (125 MHz, CDCl₃) 24.14, 24.28, 26.88, 27.28, 27.39, 27.45, 27.75, 28.58, 34.90, 35.36, 35, 55, 35.81, 36.02, 36.31, 37.21, 37.54, 38.59, 38.99, 69.67, 72.91, 73.73, 76.36, 111.85, 112.02, 125.10, 125.34, 127.01, 135.28, 136.33, 138.03, 146.18, 146.37, 148.94, 154.35; MS *m*/*z* (ES) 609 (M⁺ + H, 100%), 593 (10).

General procedure for the synthesis of N,N'-dioxides

m-Chloroperoxybenzoic acid (50–55%, 2.5 equiv.) was added, in small portions, to a stirred solution of bipyridine (1 mmol) in dichloromethane (20 ml) at 0 °C, and the stirring continued at room temperature overnight. The reaction mixture was washed, successively, with saturated Na₂SO₃ solution (10 ml), Na₂CO₃ solution (2 × 5 ml) and water. The organic layer was dried (Na₂SO₄), concentrated under reduced pressure, and the residue obtained purified by column chromatography (10% MeOH in CHCl₃) to furnish the corresponding N,N'-dioxide as a white crystalline solid.

(3a*S*,9b*R*,3a'*S*,9b'*R*)-2,2,2',2'-Tetramethyl-3a,4,5,9b,3a',4',5',9b'octahydro-[8,8'] bi[[1,3]-dioxolo[4,5*h*]quinolinyl] *N*,*N*'-dioxide 2J

Bipyridine **2F** (0.5 g, 1.13 mmol) gave N,N'-dioxide **2J** (0.38 g, 72%); mp 249 °C (from CHCl₃); $[\alpha]_D$ +256 (*c* 0.9, CHCl₃); (Found:

C, 64.9; H, 6.6; N, 6.5. $C_{24}H_{28}N_2O_6$ requires C, 65.4; H, 6.4; N, 6.4%); δ_H (300 MHz, CDCl₃) 1.40 (6H, s, 2 × Me), 1.48 (6H, s, 2 × Me), 1.79 (2H, m, H-4, H-4'), 2.21 (2H, m, H-4", H-4"'), 2.60 (2H, m, H-5, H-5'), 3.02 (2H, m, H-5", H-5"'), 4.69 (2H, m, H-3a, H-3a'), 5.72 (2H, d, $J_{9b,3a}$ 6.8, H-9b, H-9b'), 7.09 (2H, d, $J_{6,7}$ 8.1 H-6, H-6'), 7.66 (2H, d, $J_{7,6}$ 8.1, H-7, H-7'); δ_C (125 MHz, CDCl₃) 23.55, 24.80, 26.92, 27.07, 69.17, 72.64, 108.73, 124.13, 127.48, 138.73, 140.33, 145.46; m/z (LSIMS) 441 (M⁺ + H, 100%), 440 (M⁺, 14%).

(3aS,9bR,3a'S,9b'R)-2,2,7,2',2',7'-Hexamethyl-3a,4,5,9b,3a',4',5',9b'-octahydro-[8,8']bi[[1,3]dioxolo[4,5*h*]quinolinyl]*N,N'*-dioxide 3J_P

Bipyridine 3F (0.2 g, 0.45 mmol) yielded N,N'-dioxide 3J as a mixture (8:1) of atropisomers $(\mathbf{3J}_P:\mathbf{3J}_M)$. These were separated by multi-elution PLC (EtOAc) to afford the major dioxide (+)-**3J**_P (0.096 g, 45%); mp 289 °C (from EtOAc–MeOH); [α]_D +119 (c 0.63, CHCl₃); HRMS (EI) (Found: $M^+ - 2 \times O$, 436.2343. C₂₆H₃₂N₂O₆ requires 436.2363); δ_H (300 MHz, CDCl₃) 1.34 (6H, s, 2 × Me), 1.45 (6H, s, 2 × Me), 1.80 (2H, m, H-4, H-4'), 2.10 (6H, m, 2 × ArMe), 2.19 (2H, m, H-4", H-4""), 2.58 (2H, ddd, J_{5,4"} 3.8, J_{5,4} 3.8, J_{5,5"} 15.4, H-5, H-5'), 3.00 (2H, ddd, J_{5",4} 3.9, J_{5",4"} 12.5, J_{5",5} 15.4, H-5", H-5"'), 4.66 (2H, m, H-3a, H-3a'), 5.68 (2H, d, J_{9b,3a} 6.6, H-9b, H-9b'), 6.97 (2H, s, H-6, H-6'); δ_C (125 MHz, CDCl₃) 18.19, 23.71, 25.44, 27.22, 27.41, 69.86, 73.12, 109.05, 126.80, 136.46, 137.73, 141.28, 143.27; MS *m*/*z* (EI) 436 (M⁺ – 2× O, 3%), 451 (5), 368 (3), 284 (10), 256 (20), 213 (15), 129 (35), 97 (70), 83 (78), 71 (100). The atropisomer $3J_M$ was only identified as a minor component of the mixture, ¹H NMR $\delta_{\rm H}$ (300 MHz, $CDCl_3$) 1.38 (6H, s, 2 × Me), 1.44 (6H, s, 2 × Me), 1.74 (2H, m, H-4, H-4'), 2.04 (6H, m, 2 × ArMe), 2.23 (2H, m, H-4", H-4"'), 2.57 (2H, ddd, J_{5,4"} 3.8, J_{5,4} 3.8, J_{5,5"} 15.4, H-5, H-5'), 3.04 (2H, ddd, J_{5",4} 3.9, J_{5",4"} 12.5, J_{5",5} 15.4, H-5", H-5"'), 4.59 (2H, m, H-3a, H-3a'), 5.64 (2H, d, J_{9b,3a} 6.6, H-9b, H-9b'), 6.94 (2H, s, H-6, H-6').

(3a*S*,9b*R*,3a'*S*,9b'*R*)-2,2,2',2'-Tetraethyl-3a,4,5,9b,3a',4',5',9b'octahydro-[8,8'] bi[[1,3]-dioxolo[4,5*h*]quinolinyl] *N*,N'-dioxide 4J

Bipyridine **4F** (0.5 g, 1 mmol) afforded *N*,*N'*-dioxide **4J** (0.42 g, 80%); mp 267–268 °C (from MeOH); $[\alpha]_D$ +347 (*c* 1.19, CHCl₃); (Found: C, 67.6; H, 7.1; N, 5.5. C₂₈H₃₆N₂O₆ requires C, 67.7; H, 7.3; N, 5.6%); $\delta_{\rm H}$ (300 MHz, CDCl₃) 0.75 (6H, t, *J* 7.5, 2×CH₂*Me*), 0.95 (6H, t, *J* 7.5, 2×CH₂*Me*), 1.57-1.78 (10H, m, 4×*CH*₂Me, H-4, H-4'), 2.30 (2H, m, H-4", H-4"), 2.59 (2H, ddd, *J*_{5,4"} 3.7, *J*_{5,4} 3.7, *J*_{5,5"} 15.1, H-5, H-5'), 3.05 (2H, ddd, *J*_{5",4} 3.9, *J*_{5",4"} 11.4, *J*_{5",5} 15.1, H-5", H-5"), 4.67 (2H, m, H-3a, H-3a'), 5.72 (2H, d, *J*_{9b,3a} 6.9, H-9b, H-9b'), 7.07 (2H, d, *J*_{6,7} 8.1 H-6, H-6'), 7.61 (2H, d, *J*_{7,6} 8.1, H-7, H-7'); $\delta_{\rm C}$ (125 MHz, CDCl₃) 7.36, 8.36, 9.55, 23.69, 27.68, 29.67, 69.69, 73.28, 112.71, 124.46, 127.64, 139.19, 141.38, 146.16; MS *m*/*z* (EI) 496 (M⁺, 6%), 435 (52), 379 (57), 293 (61), 256 (60), 213 (28), 185 (38), 171 (26), 129 (65), 83 (100); IR *v*_{max} 1053.0, 1079.8, 1173.5, 1267.0,1280.5, 1343.8, 1456.8.

(3a*S*,9b*R*,3a'*S*,9b'*R*)-8,8'-bis{Spiro[[1,3]dioxolo[4,5h]quinoline-2,1'-cyclohexane]} *N*,*N*'-dioxide 5J

Bipyridine **5F** (0.6 g, 1.15 mmol) yielded N,N'-dioxide **5J** (0.48 g, 76%); mp 326 °C with decomposition (from CHCl₃–MeOH); [α]_D +340 (c 0.75, CHCl₃); (Found: C, 69.2; H, 6.8; N, 5.2. C₃₀H₃₆N₂O₆

requires C, 69.2; H, 7.0; N, 5.4%); $\delta_{\rm H}$ (300 MHz, CDCl₃) 1.27-1.59 (22H, m, 2 × (CH₂)₅, H-4, H-4'), 2.23 (2H, m, H-4", H-4"), 2.59 (2H, ddd, $J_{5,4"}$ 4.0, $J_{5,5}$, 15.6, H-5, H-5'), 3.05 (2H, ddd, $J_{5",4}$ 3.6, $J_{5",4"}$ 12.0, $J_{5",5}$ 15.6, H-5", H-5"), 4.74 (2H, m, H-3a, H-3a'), 5.75 (2H, d, $J_{9b,3a}$ 6.6, H-9b, H-9b'), 7.07 (2H, d, $J_{6,7}$ 8.1, H-6, H-6'), 7.59 (2H, d, $J_{7,6}$ 8.1, H-7, H-7'); $\delta_{\rm C}$ (125 MHz, CDCl₃) 24.47, 24.92, 25.51, 27.59, 34.36, 37.14, 69.08, 72.90, 109.70, 124.45, 127.92, 139.55, 141.29, 145.97; MS *m*/*z* (EI) 520 (M⁺, 3%), 368 (20), 353 (5), 256 (25), 185 (22), 129 (35), 111 (48), 97 (86), 83 (100).

(2*S*,3a*S*,9b*R*,2'*S*,3a'*S*,9b'*R*)-2,2'-di-*tert*-Butyl-3a,4,5,9b,3a',4',5',9b'-octahydro-2,2'-dimethyl-[8,8']bi[[1,3]dioxolo[4,5*h*]quinolinyl] *N*,*N*'-dioxide 6J

Bipyridine **6F** (0.4 g, 0.79 mmol) gave N,N'-dioxide **6J** (0.29 g, 70%); mp 267 °C (from EtOAc–hexane); $[\alpha]_D +254$ (*c* 0.47, CHCl₃); HRMS (ES) (Found: M⁺+H, 525.2943. C₃₀H₄₁N₂O₆ requires 525.2965); δ_H (500 MHz, CDCl₃) 0.90 [18H, s, 2 × C(Me)₃], 1.41 (6H, s, 2 × Me), 1.76 (2H, m, H-4, H-4'), 2.32 (2H, m, H-4'', H-4'''), 2.55 (2H, ddd, $J_{5,4''}$ 3.7, $J_{5,4}$ 3.7, $J_{5,5''}$ 15.5, H-5', H-5'), 3.08 (2H, ddd, $J_{5'',4}$ 3.9, $J_{5'',4''}$ 12.6, $J_{5'',5}$ 15.5, H-5''', H-5'''), 4.72 (2H, m, H-3a, H-3a'), 5.76 (2H, d, $J_{9,3a}$ 7.0, H-9b, H-9b'), 7.04 (2H, d, $J_{6,7}$ 8.1, H-6, H-6'), 7.73 (2H, d, $J_{7,6}$ 8.1, H-7, H-7'); δ_C (125 MHz, CDCl₃) 17.97, 23.61, 25.31, 27.04, 38.16, 68.97, 71.99, 113.32, 123.82, 127.25, 138.55, 140.29, 145.67; MS *m/z* (ES) 525 (M⁺+H, 58%), 510 (6).

(3a*S*,9b*R*,3a'*S*,9b'*R*)-8,8'-bis{Spiro[[1,3]dioxolo[4,5h]quinoline-2,2'-adamantane]} *N*,*N*'-dioxide 7J

Bipyridine 7F (0.5 g, 0.8 mmol) gave *N*,*N*'-dioxide 7J (0.35 g, 66%); mp 308 °C (decomp.; from EtOAc–MeOH); $[\alpha]_{\rm D}$ +435 (*c* 1.01, CHCl₃); HRMS (ES) (Found: M⁺ + H, 625.3269. C₃₈H₄₅N₂O₆ requires 625.3278); $\delta_{\rm H}$ (300 MHz, CDCl₃) 1.46-1.74 (28H, m, 2 × adamantyl protons), 1.96 (2H, m, H-4, H-4'), 2.17 (2H, m, H-4", H-4"'), 2.58 (2H, ddd, *J*_{5,4"} 3.9, *J*_{5,4} 3.9, *J*_{5,5"} 15.6, H-5, H-5'), 2.98 (2H, ddd, *J*_{5",4} 3.6, *J*_{5",4"} 11.7, *J*_{5",5} 15.6, H-5", H-5"'), 4.63 (2H, m, H-3a, H-3a'), 5.81 (2H, d, *J*_{9b,3a} 6.6, H-9b, H-9b'), 7.08 (2H, d, *J*_{6,7} 8.0, H-6, H-6'), 7.46 (2H, d, *J*_{7,6} 8.0, H-7, H-7'); $\delta_{\rm C}$ (125 MHz, CDCl₃) 24.36, 27.34, 27.48, 28.35, 34.69, 35.07, 35.32, 35.67, 37.53, 38.63, 68.53, 72.72, 111.87, 124.30, 127.17, 139.74, 140.19, 141.66, 146.02; MS *m*/*z* (ES) 625 (M⁺+H, 100%), 609 (5), 483 (30), 224 (30), 211 (84), 196 (92), 181 (30).

Acknowledgements

We thank CenTACat (to LS), DEL/CAST (to DM), and Science Foundation Ireland (Grant No. 04/IN3/B581, to NDS) for

funding, and Dr Mary F. Mahon, University of Bath, for assistance with the X-ray data collection for compounds $3I_p$ and $3J_p$.

References

- (a) S. M. Resnick, K. Lee and D. T. Gibson, J. Ind. Microbiol. Biotechnol., 1996, 17, 438; (b) D. R. Boyd and G. N. Sheldrake, Nat. Prod. Rep., 1998, 15, 309; (c) T. Hudlicky, D. Gonzalez and D. T. Gibson, Aldrichim. Acta, 1999, 32, 35; (d) D. T. Gibson and R. E. Parales, Curr. Opin. Biotechnol., 2000, 11, 236; (e) D. R. Boyd, N. D. Sharma and C. C. R. Allen, Curr. Opin. Biotechnol., 2001, 12, 564; (f) R. A. Johnson, Org. Reactions, 2004, 63, 117; (g) D. R. Boyd and T. Bugg, Org. Biomol. Chem., 2006, 4, 181; (h) K. A. B. Austin, M. Matveenko, T. A. Reekie and M. G. Banwell, Chem. Aust., 2008, 75, 3; (i) T. Hudlicky and J. W. Reed, Synlett, 2009, 685.
- 2 (a) D. R. Boyd, N. D. Sharma, N. I. Bowers, P. A. Goodrich, M. R. Groocock, A. J. Blacker, D. A. Clarke, T. Howard and H. Dalton, *Tetrahedron: Asymmetry*, 1996, **7**, 1559; (b) D. R. Boyd, N. D. Sharma, L. Sbircea, D. Murphy, T. Belhocine, J. F. Malone, S. L. James, C. C. R. Allen and J. T. G. Hamilton, *Chem. Commun.*, 2008, 5535; (c) D. R. Boyd, N. D. Sharma, V. Ljubez, J. F. Malone and C. C. R. Allen, *J. Chem. Technol. Biotechnol.*, 2007, **82**, 1072; (d) L. Sbircea, N. D. Sharma, W. Clegg, R. W. Harrington, P. N. Horton, M. B. Hursthouse, D. C. Appelby, D. R. Boyd and S. L. James, *Chem. Commun.*, 2008, 5538; (e) D. R. Boyd, M.V. Berberian, K. Dunne, C. Hardacre, B. Kelly, J. F. Malone, S. T. McGregor, M. Kaik, N. D. Sharma, P. Stevenson, manuscript submitted.
- 3 D. R. Boyd, N. D. Sharma, M. R. J. Dorrity, M. V. Hand, R. A. S. McMordie, J. F. Malone, H. P. Porter, J. Chima, H. Dalton and G. N. Sheldrake, J. Chem. Soc., Perkin Trans. 1, 1993, 1065.
- 4 D. R. Boyd, N. D. Sharma, L. V. Modyanova, J. G. Carroll, J. F. Malone, C. C. R. Allen, J. T. G. Hamilton, D. T. Gibson, R. E. Parales and H. Dalton, *Can. J. Chem.*, 2002, **80**, 589.
- 5 C. Bolm, M. Zehnder and D. Bur, *Angew. Chem., Int. Ed. Engl.*, 1990, **29**, 205.
- 6 C. Schneider, A. R. Sreekanth and E. Mai, *Angew. Chem., Int. Ed.*, 2004, 43, 5691.
- 7 S. Azoulay, K. Manabe and S. Kobayashi, Org. Lett., 2005, 7, 4593.
- 8 (a) G. Chelucci and R. P. Thummel, *Chem. Rev.*, 2002, **102**, 3129;
 (b) A. V. Malkov and P. Kocovsky, *Curr. Org. Chem.*, 2003, **7**, 1737;
 (c) A. V. Malkov and P. Kocovsky, *Eur. J. Org. Chem.*, 2007, 29; (d) M. Benaglia, S. Guizzetti and L. Pignataro, *Coord. Chem. Rev.*, 2008, **252**, 492.
- 9 (a) A. V. Malkov, M. Orsini, D. Pernazza, K. W. Muir, V. Langer, P. Meghani and P. Kocovsky, *Org. Lett.*, 2002, **4**, 1047; (b) A. V. Malkov, M. Bell, M. Orsini, D. Pernazza, K. W. Muir, A. Massa, P. Herrmann and P. Kocovsky, *J. Org. Chem.*, 2003, **68**, 9659; (c) A. V. Malkov, M. A. Kabeshov, M. Barlog and P. Kocovsky, *Chem.–Eur. J.*, 2009, **15**, 1570.
- 10 (a) R. Hrdina, T. Boyd, I. Valterova, J. Hodacova and M. Kotara, Synlett, 2009, 3141; (b) R. Hrdina, F. Opekar, J. Roithova and M. Kotara, Chem. Commun., 2009, 2314; (c) R. Hrdina, M. Dracinsky, I. Valterova, J. Hodacova, I. Cisarova and M. Kotara, Adv. Synth. Catal., 2008, 350, 1449; (d) A Kadlčíková, R. Hrdina, I. Valterová and M. Kotara, Adv. Synth. Catal., 2009, 351, 1279.
- 11 M. Nakajima, M. Saito, M. Shiro and S. Hashimoto, J. Am. Chem. Soc., 1998, 120, 6419.
- 12 G. Chelucci, G. Murineddu and G. A. Pinna, *Tetrahedron: Asymmetry*, 2004, 15, 1373.